실시간
FierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPOEndpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchBioPharma DiveSummit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBioPharma DiveModerna sees revenue bump from international COVID vaccine salesEndpoints NewsSamsung Biologics workers begin five-day strike over wage disputesFierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumbleEndpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from ChinaEndpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc LiveEndpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B dealBioWorldDermatology specialist Leo Pharma makes a $50M move into gene therapyBioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookFierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continues
Endpoints News 2026년 5월 1일

Amgen files update to Tavneos label as FDA escalates push to withdraw

Amgen files update to Tavneos label as FDA escalates push to withdraw

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.